Macular corneal dystrophy
MONDO:0009020Macular corneal dystrophy (MCD) is a rare, severe form of stromal corneal dystrophy characterized by bilateral ill-defined cloudy regions within a hazy stroma, and eventually severe visual impairment.
Also known as: Fehr corneal dystrophy, MCD, corneal dystrophy Groenouw type II, macular corneal dystrophy, Groenouw type 2 corneal dystrophy, Groenouw type II corneal dystrophy, Mcdc1, Mcdc1, formerly
43 clinical trials for this condition and its sub-types, 13 tagged with Macular corneal dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare disease: rituximab trial in malawi
Disease control CompletedThis phase II trial tests the drug rituximab (Rituxan) as a first treatment for multicentric Castleman disease, a rare immune disorder, in 15 adults in Malawi. Some high-risk patients also receive etoposide. The study aims to see if rituximab is safe and works better than standar…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Immune cells may hold key to predicting kidney disease relapse
Knowledge-focused CompletedThis study looks at immune cell patterns in people with three types of nephrotic syndrome—membranous nephropathy, minimal change disease, and focal segmental glomerulosclerosis. Researchers aim to see if certain immune cells can serve as biomarkers to track how well a patient res…
Sponsor: University Hospital, Ioannina • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC